EPHA5 and ovarian cancer: A longer follow-up would have provided a more robust assessment of the patient’s response to therapy and potential late-emerging resistance mechanisms, offering deeper insights into the prognostic implications of BTK and EPHA5 mutations in ovarian cancer metastasis.